ClinicalTrials.gg
CompletedNCT06926673Updated Jul 3, 2025Results posted

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3

A Phase 2 interventional study of Dostarlimab and Belrestotug. in Neoplasms, sponsored by GlaxoSmithKline. Completed at 15 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-03.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 3 months after the study started (first participant enrolled Dec 2021, registered Apr 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study will assess safety and pharmacokinetics and pharmacodynamics (PK/PD) of novel regimens (Dostarlimab plus belrestotug , and Dostarlimab plus belrestotug plus nelistotug) in participants with previously treated NSCLC.

02

Conditions studied

  • Neoplasms

Browse trials for

Keywords

  • NSCLC
  • Dostarlimab
  • Belrestotug
  • Nelistotug
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 62 is close to the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants capable of giving signed /assent.
  • Male or female, aged 18 years or older at the time consent is obtained.
  • Participants with or cytologically confirmed diagnosis of NSCLC (squamous or non-squamous) and

    1. Documented disease progression based on radiographic imaging, during or after a maximum of 2 for locally/regionally advanced recurrent, Stage IIIb/Stage IIIc/Stage IV or disease. Two components of treatment must have been received in the same line or as separate lines of therapy: i) No more than or less than 1 line of platinum-containing chemotherapy regimen, and ii) No more than or less than 1 line of Programmed cell death ligand 1 (PD[L]1) monoclonal antibody (mAb) containing regimen.
    2. Participants with known V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) molecular alterations must have had disease progression after receiving the locally available SoC treatment for the molecular alteration.
    3. Participants who received prior anti-PD(L)1 therapy must fulfill the following requirements: i) Have achieved a CR, PR or SD and subsequently had disease progression (per 1.1 criteria) either on or after completing PD(L)1 therapy ii) Have not progressed or recurred within the first 12 weeks of PD(L)1 therapy, either clinically or per RECIST 1.1 criteria
  • , presenting with at least 1 measurable lesion per RECIST 1.1.
  • (ECOG) Performance Status (PS) score of 0 or 1.
  • A tumor tissue sample obtained at any time from the initial diagnosis of NSCLC to time of study entry is mandatory. Although a fresh tumor tissue sample obtained during screening is preferred, is acceptable.
  • Adequate organ function as defined in the protocol.
  • A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions apply:

    i) Not a woman of (WOCBP) as defined in the protocol or ii) A WOCBP who agrees to follow the protocol defined guidance during the treatment period and for at least 120 days after the last dose of study treatment.

  • of at least 12 weeks.

Exclusion criteria

Exclusion Criteria:

Participants who received prior treatment with the following therapies (calculation is based on date of last therapy to date of first dose of study treatment):

  1. Docetaxel at any time.
  2. Any of the agents being tested in the current study.
  3. Systemic approved or investigational anticancer therapy within 30 days or 5 half-lives of the drug, whichever is shorter. At least 14 days must have elapsed between the last dose of prior anticancer agent and the first dose of study drug administered.
  4. Prior radiation therapy: permissible if at least one non-irradiated is available for assessment per version 1.1 or if a solitary measurable lesion was irradiated, objective progression is documented. A wash out of at least 2 weeks before start of study drug for radiation of any intended use is required.

    • Received greater than (>) 2 for NSCLC, including participants with BRAF molecular alternations.
    • Invasive or history of invasive malignancy other than disease under study within the last 2 years.
    • Carcinomatous meningitis (regardless of clinical status) and uncontrolled or symptomatic Central nervous system (CNS) .
    • Major surgery less than or equal to (\<=) 28 days of first dose of study treatment.
    • disease (current or history) or syndrome that required systemic treatment within the past 2 years. Replacement therapies which include physiological doses of for treatment of endocrinopathies (for example, adrenal insufficiency) are not considered systemic treatments.
    • Receiving systemic steroids (>10 milligrams [mg]) oral prednisone or equivalent) or other agents within 7 days prior to first dose of study treatment. Steroids as premedication for reactions (e.g., computed tomography [CT] scan premedication) are permitted.
    • Prior allogeneic/autologous bone marrow or solid organ transplantation.
    • Receipt of any within 30 days prior to first dose of study treatment.
    • Toxicity from previous anticancer treatment that includes:

1. Greater than or equal to (>=) Grade 3 toxicity considered related to prior immunotherapy and that led to treatment discontinuation.

2. History of myocarditis of any grade during a previous treatment with immunotherapy 3. Toxicity related to prior treatment that has not resolved to \<= Grade 1 (except alopecia, hearing loss, endocrinopathy managed with replacement therapy, and peripheral neuropathy which must be \<= Grade 2).

  • History (current and past) of idiopathic pulmonary fibrosis, pneumonitis (for pastpneumonitis exclusion only if steroids were required for treatment), interstitial lung disease, or organizing pneumonia.
  • Recent history (within the past 6 months) of uncontrolled symptomatic ascites, pleural or pericardial effusions.
  • Recent history (within the past 6 months) of gastrointestinal obstruction that required surgery, acute diverticulitis, inflammatory bowel disease, or intra-abdominal abscess.
  • History or evidence of cardiac abnormalities within the 6 months prior to enrollment which include

    1. Serious, uncontrolled cardiac arrhythmia or abnormalities including second degree (Type II) or third degree atrioventricular block.
    2. Cardiomyopathy, myocardial infarction, acute coronary syndromes (including unstable angina pectoris), coronary angioplasty, stenting or bypass grafting.
    3. Symptomatic pericarditis.
  • Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypo-albuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis.
  • Active infection requiring systemic therapy \<=7 days prior to first dose of study treatment.
  • Participants with known infection.
  • Participants with history of severe hypersensitivity to mAbs or hypersensitivity to any of the study treatment(s) or their .
  • Any serious and/or unstable pre-existing medical (aside from malignancy), psychiatric disorder, or other condition that could interfere with participant's safety, obtaining , or compliance to the study procedures in the opinion of the investigator.
  • Pregnant or lactating female participants.
  • Participant who is currently participating in or has participated in a study of an investigational device within 4 weeks prior to the first dose of study treatment.
  • Participants with presence of surface antigen (HBsAg) at screening or within 3 months prior to first dose of study intervention.
  • Participants with positive antibody test result at screening or within 3 months prior to first dose of study intervention.
  • Participants with positive hepatitis C ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study treatment.
  • Receipt of transfusion of blood products (including or red blood cells) or administration of colony-stimulating factors (including granulocyte colony stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor, and recombinant erythropoietin) within 14 days before the first dose of study intervention.
  • Known hypersensitivity to components or excipients of dostarlimab, belrestotug, and/or nelistotug
  • Has received prior antibodies or drugs targeting TIGIT, CD96, PVRIG, or other therapies targeting the CD226 axis pathway
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Dostarlimab plus Belrestotug

    Drug: Dostarlimab · Drug: Belrestotug.

  • Experimental
    Dostarlimab plus Belrestotug plus Nelistotug

    Drug: Dostarlimab · Drug: Belrestotug. · Drug: Nelistotug

Interventions

  • Dostarlimab will be administered

  • DrugBelrestotug.

    Belrestotug will be administered

  • Nelistotug will be administered.

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (Arm 4)

    An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, is life threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/ incapacity, is a congenital anomaly/ birth defect, other situations and is associated with liver injury or impaired liver function. SAEs are subset of AEs. A TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

    Time frame: Up to approximately 97 weeks

  2. Part 1: Number of Participants With Any TEAEs and SAEs (Arm 5)

    An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, is life threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/ incapacity, is a congenital anomaly/ birth defect, other situations and is associated with liver injury or impaired liver function. SAEs are subset of AEs. A TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

    Time frame: Up to approximately 107 weeks

  3. Part 1: Number of Participants With Dose Limiting Toxicity (DLT) (Arm 4 and Arm 5)

    A DLT is an AE meeting criteria such as, hematologic toxicities of Grade (G) 4 neutropenia/anemia/thrombocytopenia (G3 if bleeding). Non-hematological toxicities include persistent G2 eye events, colitis/diarrhea (G2 unresolved to ≤ G1 within 7 days despite immunosuppressive therapy, G3 for ≥ 72 hours, any G4), G3 pneumonitis, rash (unresolved to ≤ G2 within 2 weeks despite treatment), hypersensitivity/IRR, liver events meeting Hy's Law criteria. G3 toxicity unresolved to ≤G1 or baseline within 3 days with supportive care, or any G4 toxicity. Exclusions include G3 events of electrolyte imbalances correctable within 72 hours without effects, nausea/vomiting/fatigue resolving within 7 days, lymphopenia, and enzyme elevations without pancreatitis. Considerations for DLTs include permanent treatment discontinuation, investigator/sponsor judgment-based events including post-observation period toxicities.

    Time frame: Up to 21 days

  4. Part 1: Number of Participants Requiring Dose Modifications (Arm 4)

    Number of participants with dose modifications (missed doses, dose delays and infusion interruptions) is summarized.

    Time frame: Up to approximately 97 weeks

  5. Part 1: Number of Participants Requiring Dose Modifications (Arm 5)

    Number of participants with dose modifications (missed doses, dose delays and infusion interruptions) is summarized.

    Time frame: Up to approximately 107 weeks

  6. Part 1: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (Arm 4)

    Performance Status was assessed using the ECOG scale (Grades 0-5), where 0: Fully active, able to carry on all pre-disease performance without restriction. Grade 1: Restricted in physically strenuous activity but ambulatory \& able to carry out work of light or sedentary nature; Grade 2 - Ambulatory \& capable of all self-care but unable to carry out any work activities. Up and about more than (\>) 50% of waking hours; Grade 3 -Capable of only limited self-care, confined to bed or chair \> 50% of waking hours; Grade 4 -Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair; Grade 5 -Dead.

    Time frame: Up to approximately 97 weeks

  7. Part 1: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (Arm 5)

    Performance Status was assessed using the ECOG scale (Grades 0-5), where 0: Fully active, able to carry on all pre-disease performance without restriction. Grade 1: Restricted in physically strenuous activity but ambulatory \& able to carry out work of light or sedentary nature; Grade 2 - Ambulatory \& capable of all self-care but unable to carry out any work activities. Up and about more than (\>) 50% of waking hours; Grade 3 -Capable of only limited self-care, confined to bed or chair \> 50% of waking hours; Grade 4 -Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair; Grade 5 -Dead

    Time frame: Up to approximately 107 weeks

  8. Part 1: Number of Participants With Worst-case Post Baseline Increase From Baseline in Vital Signs (Arm 4)

    Vital signs including systolic blood pressure (SBP), diastolic BP (DBP), pulse rate (PR) and body temperature (BT) were measured for the participants. DBP: Grade 0 (\<80 millimeters of mercury \[mmHg\]), Grade 1 (80-89 mmHg), Grade 2 (90-99 mmHg), Grade 3 (\>=100 mmHg); SBP: Grade 0 (\<120 mmHg), Grade 1 (120-139 mmHg), Grade 2 (140-159 mmHg), Grade 3 (\>=160 mmHg); PR categories include: 'Decrease to \< 60 beats per minutes \[bpm\]', 'Change to Normal' or 'No Change', and 'Increase to \>100 bpm'; BT categories include 'Decrease to \<=35 degrees Celsius °C', 'Change to Normal' or 'No Change', and 'Increase to \>=38 °C'. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

    Time frame: Up to approximately 97 weeks

  9. Part 1: Number of Participants With Worst-case Post Baseline Increase From Baseline in Vital Signs (Arm 5)

    Vital signs including systolic blood pressure (SBP), diastolic BP (DBP), pulse rate (PR) and body temperature (BT) were measured for the participants. DBP: Grade 0 (\<80 millimeters of mercury \[mmHg\]), Grade 1 (80-89 mmHg), Grade 2 (90-99 mmHg), Grade 3 (\>=100 mmHg); SBP: Grade 0 (\<120 mmHg), Grade 1 (120-139 mmHg), Grade 2 (140-159 mmHg), Grade 3 (\>=160 mmHg); PR categories include: 'Decrease to \< 60 beats per minutes \[bpm\]', 'Change to Normal' or 'No Change', and 'Increase to \>100 bpm'; BT categories include 'Decrease to \<=35 degrees Celsius °C', 'Change to Normal' or 'No Change', and 'Increase to \>=38 °C'. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

    Time frame: Up to approximately 107 weeks

  10. Part 1: Number of Participants Who Received Concomitant Medications (Arm 4)

    Number of participants who received Concomitant medications is summarized.

    Time frame: Up to approximately 97 weeks

  11. Part 1: Number of Participants Who Received Concomitant Medications (Arm 5)

    Number of participants who received Concomitant medications is summarized.

    Time frame: Up to approximately 107 weeks

  12. Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline Electrocardiogram (ECG) Findings (Arm 4)

    Number of participants with worst-case post baseline (WCPB) from baseline ECG findings is summarized as clinically significant. Data is summarized as Normal, Abnormal - Not Clinically Significant (NCS) and Abnormal - Clinically Significant (CS). Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

    Time frame: Up to approximately 97 weeks

  13. Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline ECG Findings (Arm 5)

    Number of participants with worst-case post baseline (WCPB) from baseline ECG findings is summarized as clinically significant. Data is summarized as Normal, Abnormal - Not Clinically Significant (NCS) and Abnormal - Clinically Significant (CS). Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

    Time frame: Up to approximately 107 weeks

  14. Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline in QTcF Interval (Arm 4)

    The QTcF values based on Fridericia formula were rounded to the integer and the values are categorized into the following ranges, inclusively: Grade 0 (\<450 millisecond (msec)), Grade 1 (≥450-≤480 msec), Grade 2 (≥481-≤500 msec), and Grade 3 (≥501 msec). Missing baseline grades were assumed to be Grade 0. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

    Time frame: Up to approximately 97 weeks

  15. Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline in QTcF Interval (Arm 5)

    The QTcF values based on Fridericia formula were rounded to the integer and the values are categorized into the following ranges, inclusively: Grade 0 (\<450 millisecond (msec)), Grade 1 (≥450-≤480 msec), Grade 2 (≥481-≤500 msec), and Grade 3 (≥501 msec). Missing baseline grades were assumed to be Grade 0. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

    Time frame: Up to approximately 107 weeks

  16. Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline in Left Ventricular Ejection Fraction (LVEF) (Arm 4)

    Number of participants with worst case post-baseline in LVEF from baseline is summarized as 'any decrease (\>0%-\<10% Decrease, 10%-19% Decrease, \>=20% Decrease)', '\>=10% Decrease and \>= Lower limit of normal (LLN)', '\>=10% Decrease and \< LLN', '\>=20% Decrease and \>= LLN' and '\>=20% Decrease and \< LLN' . An increase is defined as an increase in grade relative to Baseline grade. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

    Time frame: Up to approximately 97 weeks

  17. Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline in Left Ventricular Ejection Fraction (LVEF) (Arm 5)

    Number of participants with worst case post-baseline in LVEF from baseline is summarized as 'any decrease (\>0%-\<10% Decrease, 10%-19% Decrease, \>=20% Decrease)', '\>=10% Decrease and \>= Lower limit of normal (LLN)', '\>=10% Decrease and \< LLN', '\>=20% Decrease and \>= LLN' and '\>=20% Decrease and \< LLN' . An increase is defined as an increase in grade relative to Baseline grade. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

    Time frame: Up to approximately 107 weeks

  18. Part 1: Number of Participants With Worst Case Hematology Results by Maximum Grade Increase Post-Baseline Relative to Baseline (Arm 4)

    Blood samples were collected for the analysis of hematology parameters and are categorized in alignment with Common Terminology Criteria for Adverse Events (CTCAE) version 5 as Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; and Grade 4: life-threatening consequences. Higher grade indicates greater severity. An increase in grade is defined relative to the Baseline grade. Participants with missing baseline values are assumed to have baseline value of grade 0. Any worst-case post baseline increase in grade along with any increase to a maximum grade of 3 and 4 is summarized. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

    Time frame: Up to approximately 97 weeks

  19. Part 1: Number of Participants With Worst Case Hematology Results by Maximum Grade Increase Post-Baseline Relative to Baseline (Arm 5)

    Blood samples were collected for the analysis of hematology parameters and are categorized in alignment with Common Terminology Criteria for Adverse Events (CTCAE) version 5 as Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; and Grade 4: life-threatening consequences. Higher grade indicates greater severity. An increase in grade is defined relative to the Baseline grade. Participants with missing baseline values are assumed to have baseline value of grade 0. Any worst-case post baseline increase in grade along with any increase to a maximum grade of 3 and 4 is summarized. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

    Time frame: Up to approximately 107 weeks

  20. Part 1: Number of Participants With Worst Case Clinical Chemistry Results by Maximum Grade Increase Post-Baseline Relative to Baseline (Arm 4)

    Blood samples were collected for the analysis of clinical chemistry parameters and are categorized in alignment with Common Terminology Criteria for Adverse Events (CTCAE) version 5 as Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; and Grade 4: life-threatening consequences. Higher grade indicates greater severity. An increase in grade is defined relative to the Baseline grade. Participants with missing baseline values are assumed to have baseline value of grade 0. Any worst-case post baseline increase in grade along with any increase to a maximum grade of 3 and 4 is summarized. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

    Time frame: Up to approximately 97 weeks

  21. Part 1: Number of Participants With Worst Case Clinical Chemistry Results by Maximum Grade Increase Post-Baseline Relative to Baseline (Arm 5)

    Blood samples were collected for the analysis of clinical chemistry parameters and are categorized in alignment with Common Terminology Criteria for Adverse Events (CTCAE) version 5 as Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; and Grade 4: life-threatening consequences. Higher grade indicates greater severity. An increase in grade is defined relative to the Baseline grade. Participants with missing baseline values are assumed to have baseline value of grade 0. Any worst-case post baseline increase in grade along with any increase to a maximum grade of 3 and 4 is summarized. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

    Time frame: Up to approximately 107 weeks

  22. Part 1: Number of Participants With Worst Case Change Post-baseline in Clinical Chemistry Parameters (Arm 4)

    Blood samples were collected for analysis of clinical chemistry. The summaries of worst-case post baseline (WCPB) from baseline (B) with respect to normal range was analyzed. Data is presented as "XXX B YYY, WCPB YYY", where XXX denotes lab parameter and YYY is high/normal/low. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

    Time frame: Up to approximately 97 weeks

  23. Part 1: Number of Participants With Worst Case Change Post-baseline in Clinical Chemistry Parameters (Arm 5)

    Blood samples were collected for analysis of clinical chemistry. The summaries of worst-case post baseline (WCPB) from baseline (B) with respect to normal range was analyzed. Data is presented as "XXX B YYY, WCPB YYY", where XXX denotes lab parameter and YYY is high/normal/low. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

    Time frame: Up to approximately 107 weeks

  24. Part 1: Number of Participants With Worst-Case Urinalysis Results Post-Baseline Relative to Baseline (Arm 4)

    Urinalysis was performed. Participants with missing value at baseline are assumed to be negative at baseline. All increases are from baseline. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Up to approximately 97 weeks

  25. Part 1: Number of Participants With Worst-Case Urinalysis Results Post-Baseline Relative to Baseline (Arm 5)

    Urinalysis was performed. Participants with missing value at baseline are assumed to be negative at baseline. All increases are from baseline. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Up to approximately 107 weeks

  26. Part 2: Overall Survival (OS)

    OS is defined as the time from date of randomization to the date of death, irrespective of the cause of death.

    Time frame: Up to approximately 107 weeks

Secondary outcomes

  1. Part 1: Objective Response Rate (ORR) (Arm 4)

    ORR is defined as the percentage of participants with a best overall confirmed Complete response (CR) or Partial response (PR) at any time as per disease-specific criteria per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Complete Response (CR) is defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline).

    Time frame: Up to approximately 97 weeks

  2. Part 1: Objective Response Rate (ORR) (Arm 5)

    ORR is defined as the percentage of participants with a best overall confirmed CR or PR at any time as per disease-specific criteria per RECIST version 1.1. CR is defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline).

    Time frame: Up to approximately 107 weeks

  3. Part 1: Disease Control Rate (DCR) (Arm 4)

    DCR is defined as the percentage of participants with a confirmed CR + PR at any time, plus SD =\>12 weeks as per RECIST v1.1. Complete Response (CR) is defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.

    Time frame: Up to approximately 97 weeks

  4. Part 1: Disease Control Rate (DCR) (Arm 5)

    DCR is defined as the percentage of participants with a confirmed CR + PR at any time, plus SD =\>12 weeks as per RECIST v1.1. Complete Response (CR) is defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.

    Time frame: Up to approximately 107 weeks

  5. Part 1: Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of Belrestotug (Arm 4)

    Blood samples were collected for pharmacokinetic analysis of Belrestotug.

    Time frame: Up to 21 days (Cycle 1)

  6. Part 1: Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of Belrestotug (Arm 5)

    Blood samples were collected for pharmacokinetic analysis of Belrestotug.

    Time frame: Up to 21 days (Cycle 1)

  7. Part 1: Cmax and Cmin of Dostarlimab (Arm 4)

    Blood samples were collected for pharmacokinetic analysis of Dostarlimab.

    Time frame: Up to 21 days (Cycle 1)

  8. Part 1: Cmax and Cmin of Dostarlimab (Arm 5)

    Blood samples were collected for pharmacokinetic analysis of Dostarlimab.

    Time frame: Up to 21 days (Cycle 1)

  9. Part 1: Cmax and Cmin of Nelistotug (Arm 5)

    Blood samples were collected for pharmacokinetic analysis of Nelistotug.

    Time frame: Up to 21 days (Cycle 1)

  10. Part 2: Survival Rate at 12 and 18 Months

    Survival rate was planned to be anaysed at 12 and 18 months

    Time frame: At 12 and 18 months

  11. Part 2: Number of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD) and Progressive Disease (PD)

    CR, PR, SD and PD was planned to be evaluated as per RECIST version 1.1 criteria. Complete Response (CR) is defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm.

    Time frame: Up to approximately 107 weeks

  12. Part 2: Progression-free Survival (PFS)

    PFS is defined as time from the date of randomization to the date of disease progression as per RECIST v1.1. or death whichever occurs earlier. Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm.

    Time frame: Up to approximately 107 weeks

  13. Part 2: Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with a best overall confirmed Complete response (CR) or Partial response (PR) at any time as per disease-specific criteria per RECIST version 1.1. Complete Response (CR) is defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline).

    Time frame: Up to approximately 107 weeks

  14. Part 2: Duration of Response (DOR)

    DOR is defined as the time for first documented evidence of CR or PR until disease progression or death, per RECIST 1.1 criteria. Complete Response (CR) is defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

    Time frame: Up to approximately 107 weeks

  15. Part 2: Disease Control Rate (DCR)

    DCR is defined as the percentage of participants with a confirmed CR + PR at any time, plus SD =\>12 weeks as per RECIST v1.1. Complete Response (CR) is defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.

    Time frame: Up to approximately 107 weeks

  16. Part 2: Number of Participants With Immune-based (i) Complete Response (iCR), Partial Response (iPR), Unconfirmed Progressive Disease (iUPD), Confirmed Progressive Disease (iCPD), and Stable Disease (iSD)

    Modified RECIST 1.1 for immune-based therapeutics (iRECIST) is based on RECIST v 1.1 but adapted to account for the unique tumor response seen with immunotherapeutic drugs. iRECIST is used to assess tumor response and progression and make treatment decisions. iCR: disappearance of all target lesions; iPR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). iCPD: either 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; iSD: stable disease in the absence of CR or PD and iUPD: unconfirmed progressive disease when PD is unconfirmed and NE: not evaluable.

    Time frame: Up to approximately 107 weeks

  17. Part 2: Progression-free Survival (iPFS)

    iPFS is defined as time from the date of randomization to the date of disease progression or death, whichever occurs earlier, per iRECIST criteria. Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm.

    Time frame: Up to approximately 107 weeks

  18. Part 2: Objective Response Rate (iORR)

    iORR is defined as the percentage of participants with a confirmed iCR or iPR at any time per iRECIST criteria. iCR is defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. iPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

    Time frame: Up to approximately 107 weeks

  19. Part 2: Duration of Response (iDOR)

    iDOR is defined as the time from first documented evidence of CR or PR until disease progression or death, per iRECIST criteria. iCR is defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. iPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

    Time frame: Up to approximately 107 weeks

  20. Part 2: Number of Participants With AEs, SAEs, Adverse Events of Special Interest (AESI), AE/SAEs Leading to Dose Modifications/Delays/Withdrawals

    An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, any other situation such as important medical events according to medical or scientific judgement. AESI are considered to be Infusion Related Reactions (IRRs) and those of potential immunologic etiology. AEs were planned to be coded using the MedDRA coding system.

    Time frame: Up to approximately 107 weeks

  21. Part 2: Number of Participants With Clinically Significant Changes in Vital Signs and Laboratory Parameters

    Clinically significant changes in vital signs were planned to be assessed. Blood samples were planned to be collected for the analysis of laboratory parameters.

    Time frame: Up to approximately 107 weeks

  22. Part 2: Cmax and Cmin for Dostarlimab

    Blood samples were planned to be collected to assess the pharmacokinetics of Dostarlimab.

    Time frame: Up to approximately 107 weeks

  23. Part 2: Cmax and Cmin for Belrestotug

    Blood samples were planned to be collected to assess the pharmacokinetics of Belrestotug.

    Time frame: Up to approximately 107 weeks

  24. Part 2: Number of Participants With Positive Anti-drug Antibodies (ADA)

    Serum samples were planned to be collected for the analysis of the presence of ADAs using validated immunoassays.

    Time frame: Up to approximately 107 weeks

07

Results

Posted Jul 3, 2025

Participant flow

Participant flow — Overall Study
MilestoneArm 4: Dostarlimab + Belrestotug [Low Dose (LD)]Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)]Arm 4: Dostarlimab + Belrestotug [High Dose (HD)]Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MDArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD
Started6991071110
Dlt evaluable population0444700
Completed6678799
Not completed0322021
Withdrew: Lost to follow-up0001000
Withdrew: Physician decision0000001
Withdrew: Withdrawal by subject0321020

Outcome measures

PrimaryPart 1: Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (Arm 4)

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, is life threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/ incapacity, is a congenital anomaly/ birth defect, other situations and is associated with liver injury or impaired liver function. SAEs are subset of AEs. A TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

Time frame:
Up to approximately 97 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (Arm 4)
ParticipantsArm 4: Dostarlimab + Belrestotug [Low Dose (LD)]Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)]Arm 4: Dostarlimab + Belrestotug [High Dose (HD)]
Any TEAEs698
Any SAEs032
PrimaryPart 1: Number of Participants With Any TEAEs and SAEs (Arm 5)

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, is life threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/ incapacity, is a congenital anomaly/ birth defect, other situations and is associated with liver injury or impaired liver function. SAEs are subset of AEs. A TEAE is any event that was not present prior to the initiation of study treatment or any event already present that worsens in either intensity or frequency following exposure to study treatment. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

Time frame:
Up to approximately 107 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Any TEAEs and SAEs (Arm 5)
ParticipantsArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MDArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD
Any TEAEs106119
Any SAEs3333
PrimaryPart 1: Number of Participants With Dose Limiting Toxicity (DLT) (Arm 4 and Arm 5)

A DLT is an AE meeting criteria such as, hematologic toxicities of Grade (G) 4 neutropenia/anemia/thrombocytopenia (G3 if bleeding). Non-hematological toxicities include persistent G2 eye events, colitis/diarrhea (G2 unresolved to ≤ G1 within 7 days despite immunosuppressive therapy, G3 for ≥ 72 hours, any G4), G3 pneumonitis, rash (unresolved to ≤ G2 within 2 weeks despite treatment), hypersensitivity/IRR, liver events meeting Hy's Law criteria. G3 toxicity unresolved to ≤G1 or baseline within 3 days with supportive care, or any G4 toxicity. Exclusions include G3 events of electrolyte imbalances correctable within 72 hours without effects, nausea/vomiting/fatigue resolving within 7 days, lymphopenia, and enzyme elevations without pancreatitis. Considerations for DLTs include permanent treatment discontinuation, investigator/sponsor judgment-based events including post-observation period toxicities.

Time frame:
Up to 21 days
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Dose Limiting Toxicity (DLT) (Arm 4 and Arm 5)
ParticipantsArm 4: Dostarlimab + Belrestotug [Medium Dose (MD)]Arm 4: Dostarlimab + Belrestotug [High Dose (HD)]Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MDArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HD
Part 1: Number of Participants With Dose Limiting Toxicity (DLT) (Arm 4 and Arm 5)0001
PrimaryPart 1: Number of Participants Requiring Dose Modifications (Arm 4)

Number of participants with dose modifications (missed doses, dose delays and infusion interruptions) is summarized.

Time frame:
Up to approximately 97 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants Requiring Dose Modifications (Arm 4)
ParticipantsArm 4: Dostarlimab + Belrestotug [Low Dose (LD)]Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)]Arm 4: Dostarlimab + Belrestotug [High Dose (HD)]
Missed Doses032
Dose Delays011
Infusion Interruptions011
PrimaryPart 1: Number of Participants Requiring Dose Modifications (Arm 5)

Number of participants with dose modifications (missed doses, dose delays and infusion interruptions) is summarized.

Time frame:
Up to approximately 107 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants Requiring Dose Modifications (Arm 5)
ParticipantsArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MDArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD
Missed Doses6256
Dose Delays1000
Infusion Interruptions0200
PrimaryPart 1: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (Arm 4)

Performance Status was assessed using the ECOG scale (Grades 0-5), where 0: Fully active, able to carry on all pre-disease performance without restriction. Grade 1: Restricted in physically strenuous activity but ambulatory \& able to carry out work of light or sedentary nature; Grade 2 - Ambulatory \& capable of all self-care but unable to carry out any work activities. Up and about more than (\>) 50% of waking hours; Grade 3 -Capable of only limited self-care, confined to bed or chair \> 50% of waking hours; Grade 4 -Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair; Grade 5 -Dead.

Time frame:
Up to approximately 97 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (Arm 4)
ParticipantsArm 4: Dostarlimab + Belrestotug [Low Dose (LD)]Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)]Arm 4: Dostarlimab + Belrestotug [High Dose (HD)]
Baseline, Grade 0053
Baseline, Grade 1646
Week 4, Grade 0143
Week 4, Grade 1334
Week 4, Grade 2211
Week 7, Grade 0121
Week 7, Grade 1115
Week 10, Grade 0121
Week 10, Grade 1013
Week 13, Grade 0111
Week 13, Grade 1021
Week 16, Grade 0111
Week 16, Grade 1020
Week 19, Grade 0101
Week 19, Grade 1030
Week 22, Grade 0100
Week 22, Grade 1021
Week 25, Grade 0—10
Week 25, Grade 1—11
Week 28, Grade 0—10
Week 28 Grade 1—11
Week 31, Grade 0—11
Week 34, Grade 0——1
Week 37, Grade 0—11
Week 40, Grade 0—1—
Week 43, Grade 0—1—
Week 46, Grade 0—1—
Week 49, Grade 0—1—
Week 52, Grade 1—1—
Week 55, Grade 1—1—
Week 58, Grade 0—1—
Week 61, Grade 0—1—
Week 64, Grade 1—1—
Week 67, Grade 1—1—
Week 70, Grade 1—1—
Treatment Discontinuation (up to 97 weeks), Grade 0110
Treatment Discontinuation (up to 97 weeks), Grade 1254
Treatment Discontinuation (up to 97 weeks), Grade 2111
Treatment Discontinuation (up to 97 weeks), Grade 3201
PrimaryPart 1: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (Arm 5)

Performance Status was assessed using the ECOG scale (Grades 0-5), where 0: Fully active, able to carry on all pre-disease performance without restriction. Grade 1: Restricted in physically strenuous activity but ambulatory \& able to carry out work of light or sedentary nature; Grade 2 - Ambulatory \& capable of all self-care but unable to carry out any work activities. Up and about more than (\>) 50% of waking hours; Grade 3 -Capable of only limited self-care, confined to bed or chair \> 50% of waking hours; Grade 4 -Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair; Grade 5 -Dead

Time frame:
Up to approximately 107 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (Arm 5)
ParticipantsArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MDArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD
Baseline, Grade 04271
Baseline, Grade 16549
Week 4, Grade 04151
Week 4, Grade 14568
Week 4, Grade 22000
Week 7, Grade 03231
Week 7, Grade 13246
Week 7, Grade 22010
Week 10, Grade 01231
Week 10, Grade 15133
Week 10, Grade 21000
Week 13, Grade 02220
Week 13, Grade 13024
Week 16, Grade 02221
Week 16, Grade 12022
Week 19, Grade 03220
Week 19, Grade 12012
Week 22, Grade 02120
Week 22, Grade 12111
Week 25, Grade 02110
Week 25, Grade 11121
Week 28, Grade 02010
Week 28, Grade 10121
Week 31, Grade 0211—
Week 34, Grade 0210—
Week 37, Grade 01—1—
Week 37, Grade 11—0—
Week 40, Grade 02—0—
Week 40, Grade 10—1—
Week 43, Grade 01—0—
Week 43, Grade 10—1—
Week 46, Grade 01—0—
Week 46, Grade 10—1—
Week 49, Grade 01—0—
Week 49, Grade 20—1—
Week 52, Grade 01———
Week 55, Grade 01———
Week 58, Grade 01———
Treatment Discontinuation (up to 107 weeks), Grade 01141
Treatment Discontinuation (up to 107 weeks), Grade 15645
Treatment Discontinuation (up to 107 weeks), Grade 21011
Treatment Discontinuation (up to 107 weeks), Grade 31000
PrimaryPart 1: Number of Participants With Worst-case Post Baseline Increase From Baseline in Vital Signs (Arm 4)

Vital signs including systolic blood pressure (SBP), diastolic BP (DBP), pulse rate (PR) and body temperature (BT) were measured for the participants. DBP: Grade 0 (\<80 millimeters of mercury \[mmHg\]), Grade 1 (80-89 mmHg), Grade 2 (90-99 mmHg), Grade 3 (\>=100 mmHg); SBP: Grade 0 (\<120 mmHg), Grade 1 (120-139 mmHg), Grade 2 (140-159 mmHg), Grade 3 (\>=160 mmHg); PR categories include: 'Decrease to \< 60 beats per minutes \[bpm\]', 'Change to Normal' or 'No Change', and 'Increase to \>100 bpm'; BT categories include 'Decrease to \<=35 degrees Celsius °C', 'Change to Normal' or 'No Change', and 'Increase to \>=38 °C'. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

Time frame:
Up to approximately 97 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Worst-case Post Baseline Increase From Baseline in Vital Signs (Arm 4)
ParticipantsArm 4: Dostarlimab + Belrestotug [Low Dose (LD)]Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)]Arm 4: Dostarlimab + Belrestotug [High Dose (HD)]
Diastolic Blood Pressure, Any Grade Increase022
Diastolic Blood Pressure, Increase to Grade 2010
Diastolic Blood Pressure, Increase to Grade 3001
Systolic Blood Pressure, Any Grade Increase123
Systolic Blood Pressure, Increase to Grade 2122
Systolic Blood Pressure, Increase to Grade 3001
Heart Rate, Decrease to <60 bpm000
Heart Rate, Change to Normal or No Change476
Heart Rate, Increase to >100 bpm222
Temperature, Decrease to <=35 °C000
Temperature, Change to Normal or No Change696
Temperature, Increase to >=38 °C002
PrimaryPart 1: Number of Participants With Worst-case Post Baseline Increase From Baseline in Vital Signs (Arm 5)

Vital signs including systolic blood pressure (SBP), diastolic BP (DBP), pulse rate (PR) and body temperature (BT) were measured for the participants. DBP: Grade 0 (\<80 millimeters of mercury \[mmHg\]), Grade 1 (80-89 mmHg), Grade 2 (90-99 mmHg), Grade 3 (\>=100 mmHg); SBP: Grade 0 (\<120 mmHg), Grade 1 (120-139 mmHg), Grade 2 (140-159 mmHg), Grade 3 (\>=160 mmHg); PR categories include: 'Decrease to \< 60 beats per minutes \[bpm\]', 'Change to Normal' or 'No Change', and 'Increase to \>100 bpm'; BT categories include 'Decrease to \<=35 degrees Celsius °C', 'Change to Normal' or 'No Change', and 'Increase to \>=38 °C'. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

Time frame:
Up to approximately 107 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Worst-case Post Baseline Increase From Baseline in Vital Signs (Arm 5)
ParticipantsArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MDArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD
Diastolic Blood Pressure, Any Grade Increase5145
Diastolic Blood Pressure, Increase to Grade 23010
Diastolic Blood Pressure, Increase to Grade 30000
Systolic Blood Pressure, Any Grade Increase4254
Systolic Blood Pressure, Increase to Grade 21121
Systolic Blood Pressure, Increase to Grade 31002
Heart Rate, Decrease to <60 bpm0000
Heart Rate, Change to Normal or No Change7797
Heart Rate, Increase to >100 bpm3022
Temperature, Decrease to <=35 C0000
Temperature, Change to Normal or No Change106119
Temperature, Increase to >=38 C0100
PrimaryPart 1: Number of Participants Who Received Concomitant Medications (Arm 4)

Number of participants who received Concomitant medications is summarized.

Time frame:
Up to approximately 97 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants Who Received Concomitant Medications (Arm 4)
ParticipantsArm 4: Dostarlimab + Belrestotug [Low Dose (LD)]Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)]Arm 4: Dostarlimab + Belrestotug [High Dose (HD)]
Part 1: Number of Participants Who Received Concomitant Medications (Arm 4)699
PrimaryPart 1: Number of Participants Who Received Concomitant Medications (Arm 5)

Number of participants who received Concomitant medications is summarized.

Time frame:
Up to approximately 107 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants Who Received Concomitant Medications (Arm 5)
ParticipantsArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MDArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD
Part 1: Number of Participants Who Received Concomitant Medications (Arm 5)1071110
PrimaryPart 1: Number of Participants With Worst-case Post Baseline Relative to Baseline Electrocardiogram (ECG) Findings (Arm 4)

Number of participants with worst-case post baseline (WCPB) from baseline ECG findings is summarized as clinically significant. Data is summarized as Normal, Abnormal - Not Clinically Significant (NCS) and Abnormal - Clinically Significant (CS). Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

Time frame:
Up to approximately 97 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline Electrocardiogram (ECG) Findings (Arm 4)
ParticipantsArm 4: Dostarlimab + Belrestotug [Low Dose (LD)]Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)]Arm 4: Dostarlimab + Belrestotug [High Dose (HD)]
Baseline — Normal424
Baseline — Abnormal - NCS263
Baseline — Abnormal - CS002
Worst-case post baseline — Normal223
Worst-case post baseline — Abnormal - NCS312
Worst-case post baseline — Abnormal - CS013
PrimaryPart 1: Number of Participants With Worst-case Post Baseline Relative to Baseline ECG Findings (Arm 5)

Number of participants with worst-case post baseline (WCPB) from baseline ECG findings is summarized as clinically significant. Data is summarized as Normal, Abnormal - Not Clinically Significant (NCS) and Abnormal - Clinically Significant (CS). Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

Time frame:
Up to approximately 107 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline ECG Findings (Arm 5)
ParticipantsArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MDArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD
Baseline — Normal5557
Baseline — Abnormal - NCS4152
Baseline — Abnormal - CS1111
Worst-case post baseline — Normal0544
Worst-case post baseline — Abnormal - NCS7245
Worst-case post baseline — Abnormal - CS3030
PrimaryPart 1: Number of Participants With Worst-case Post Baseline Relative to Baseline in QTcF Interval (Arm 4)

The QTcF values based on Fridericia formula were rounded to the integer and the values are categorized into the following ranges, inclusively: Grade 0 (\<450 millisecond (msec)), Grade 1 (≥450-≤480 msec), Grade 2 (≥481-≤500 msec), and Grade 3 (≥501 msec). Missing baseline grades were assumed to be Grade 0. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

Time frame:
Up to approximately 97 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline in QTcF Interval (Arm 4)
ParticipantsArm 4: Dostarlimab + Belrestotug [Low Dose (LD)]Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)]Arm 4: Dostarlimab + Belrestotug [High Dose (HD)]
Baseline, Grade 0468
Baseline, Grade 1100
Baseline, Grade 2011
Baseline, Grade 3110
WCPB, No Grade Increase447
WCPB, Increase to Grade 1101
PrimaryPart 1: Number of Participants With Worst-case Post Baseline Relative to Baseline in QTcF Interval (Arm 5)

The QTcF values based on Fridericia formula were rounded to the integer and the values are categorized into the following ranges, inclusively: Grade 0 (\<450 millisecond (msec)), Grade 1 (≥450-≤480 msec), Grade 2 (≥481-≤500 msec), and Grade 3 (≥501 msec). Missing baseline grades were assumed to be Grade 0. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

Time frame:
Up to approximately 107 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline in QTcF Interval (Arm 5)
ParticipantsArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MDArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD
Baseline, Grade 0106109
Baseline, Grade 10110
Baseline, Grade 20000
Baseline, Grade 30000
WCPB, No Grade Increase105118
WCPB, Increase to Grade 20200
WCPB, Increase to Grade 30001
PrimaryPart 1: Number of Participants With Worst-case Post Baseline Relative to Baseline in Left Ventricular Ejection Fraction (LVEF) (Arm 4)

Number of participants with worst case post-baseline in LVEF from baseline is summarized as 'any decrease (\>0%-\<10% Decrease, 10%-19% Decrease, \>=20% Decrease)', '\>=10% Decrease and \>= Lower limit of normal (LLN)', '\>=10% Decrease and \< LLN', '\>=20% Decrease and \>= LLN' and '\>=20% Decrease and \< LLN' . An increase is defined as an increase in grade relative to Baseline grade. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

Time frame:
Up to approximately 97 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline in Left Ventricular Ejection Fraction (LVEF) (Arm 4)
ParticipantsArm 4: Dostarlimab + Belrestotug [Low Dose (LD)]Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)]Arm 4: Dostarlimab + Belrestotug [High Dose (HD)]
No change or any increase—1—
Any Decrease—0—
>=10% Decrease and >= LLN—0—
>=10% Decrease and < LLN—0—
>=20% Decrease and >= LLN—0—
>=20% Decrease and < LLN—0—
PrimaryPart 1: Number of Participants With Worst-case Post Baseline Relative to Baseline in Left Ventricular Ejection Fraction (LVEF) (Arm 5)

Number of participants with worst case post-baseline in LVEF from baseline is summarized as 'any decrease (\>0%-\<10% Decrease, 10%-19% Decrease, \>=20% Decrease)', '\>=10% Decrease and \>= Lower limit of normal (LLN)', '\>=10% Decrease and \< LLN', '\>=20% Decrease and \>= LLN' and '\>=20% Decrease and \< LLN' . An increase is defined as an increase in grade relative to Baseline grade. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

Time frame:
Up to approximately 107 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Worst-case Post Baseline Relative to Baseline in Left Ventricular Ejection Fraction (LVEF) (Arm 5)
ParticipantsArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MDArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD
No change or any increase2—00
Any Decrease0—21
>=10% Decrease and >= LLN0—00
>=10% Decrease and < LLN0—00
>=20% Decrease and >= LLN0—00
>=20% Decrease and < LLN0—00
PrimaryPart 1: Number of Participants With Worst Case Hematology Results by Maximum Grade Increase Post-Baseline Relative to Baseline (Arm 4)

Blood samples were collected for the analysis of hematology parameters and are categorized in alignment with Common Terminology Criteria for Adverse Events (CTCAE) version 5 as Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; and Grade 4: life-threatening consequences. Higher grade indicates greater severity. An increase in grade is defined relative to the Baseline grade. Participants with missing baseline values are assumed to have baseline value of grade 0. Any worst-case post baseline increase in grade along with any increase to a maximum grade of 3 and 4 is summarized. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

Time frame:
Up to approximately 97 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Worst Case Hematology Results by Maximum Grade Increase Post-Baseline Relative to Baseline (Arm 4)
ParticipantsArm 4: Dostarlimab + Belrestotug [Low Dose (LD)]Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)]Arm 4: Dostarlimab + Belrestotug [High Dose (HD)]
Eosinophils, Any Grade Increase120
Eosinophils, Increase to Grade 3000
Eosinophils, Increase to Grade 4000
Lymphocyte count decreased, Any Grade Increase166
Lymphocyte count decreased, Increase to Grade 3012
Lymphocyte count decreased, Increase to Grade 4000
Lymphocyte count increased, Any Grade Increase000
Lymphocyte count increased, Increase to Grade 3000
Lymphocyte count increased, Increase to Grade 4000
Platelet count decreased, Any Grade Increase010
Platelet count decreased, Increase to Grade 3000
Platelet count decreased, Increase to Grade 4000
White blood cell decreased, Any Grade Increase012
White blood cell decreased, Increase to Grade 3000
White blood cell decreased, Increase to Grade 4000
Anemia, Any Grade Increase431
Anemia, Increase to Grade 3010
Anemia, Increase to Grade 4000
Hemoglobin increased, Any Grade Increase000
Hemoglobin increased, Increase to Grade 3000
Hemoglobin increased, Increase to Grade 4000
Neutrophil count decreased, Any Grade Increase000
Neutrophil count decreased, Increase to Grade 3000
Neutrophil count decreased, Increase to Grade 4000
PrimaryPart 1: Number of Participants With Worst Case Hematology Results by Maximum Grade Increase Post-Baseline Relative to Baseline (Arm 5)

Blood samples were collected for the analysis of hematology parameters and are categorized in alignment with Common Terminology Criteria for Adverse Events (CTCAE) version 5 as Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; and Grade 4: life-threatening consequences. Higher grade indicates greater severity. An increase in grade is defined relative to the Baseline grade. Participants with missing baseline values are assumed to have baseline value of grade 0. Any worst-case post baseline increase in grade along with any increase to a maximum grade of 3 and 4 is summarized. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

Time frame:
Up to approximately 107 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Worst Case Hematology Results by Maximum Grade Increase Post-Baseline Relative to Baseline (Arm 5)
ParticipantsArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MDArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD
Eosinophils, Any Grade Increase1233
Eosinophils, Increase to Grade 30000
Eosinophils, Increase to Grade 40000
Lymphocyte count decreased, Any Grade Increase8488
Lymphocyte count decreased, Increase to Grade 33143
Lymphocyte count decreased, Increase to Grade 41010
Lymphocyte count increased, Any Grade Increase0000
Lymphocyte count increased, Increase to Grade 30000
Lymphocyte count increased, Increase to Grade 40000
Platelet count decreased, Any Grade Increase1020
Platelet count decreased, Increase to Grade 30000
Platelet count decreased, Increase to Grade 40010
White blood cell decreased, Any Grade Increase0101
White blood cell decreased, Increase to Grade 30000
White blood cell decreased, Increase to Grade 40000
Anemia, Any Grade Increase6244
Anemia, Increase to Grade 31010
Anemia, Increase to Grade 40000
Hemoglobin increased, Any Grade Increase2000
Hemoglobin increased, Increase to Grade 32000
Hemoglobin increased, Increase to Grade 40000
Neutrophil count decreased, Any Grade Increase0110
Neutrophil count decreased, Increase to Grade 30010
Neutrophil count decreased, Increase to Grade 40000
PrimaryPart 1: Number of Participants With Worst Case Clinical Chemistry Results by Maximum Grade Increase Post-Baseline Relative to Baseline (Arm 4)

Blood samples were collected for the analysis of clinical chemistry parameters and are categorized in alignment with Common Terminology Criteria for Adverse Events (CTCAE) version 5 as Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; and Grade 4: life-threatening consequences. Higher grade indicates greater severity. An increase in grade is defined relative to the Baseline grade. Participants with missing baseline values are assumed to have baseline value of grade 0. Any worst-case post baseline increase in grade along with any increase to a maximum grade of 3 and 4 is summarized. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

Time frame:
Up to approximately 97 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Worst Case Clinical Chemistry Results by Maximum Grade Increase Post-Baseline Relative to Baseline (Arm 4)
ParticipantsArm 4: Dostarlimab + Belrestotug [Low Dose (LD)]Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)]Arm 4: Dostarlimab + Belrestotug [High Dose (HD)]
Activated Partial Thromboplastin Time (aPTT), Any Grade Increase000
aPTT, Increase to Grade 3000
aPTT, Increase to Grade 4000
Glucose, Any Grade Increase020
Glucose, Increase to Grade 3000
Glucose, Increase to Grade 4000
International normalized ratio (INR) increased, Any Grade Increase000
INR increased, Increase to Grade 3000
INR increased, Increase to Grade 4000
Alkaline phosphatase (AP), Any Grade Increase131
AP, Increase to Grade 3000
AP, Increase to Grade 4000
Alanine aminotransferase (ALT), Any Grade Increase120
ALT, Increase to Grade 3000
ALT, Increase to Grade 4000
Aspartate aminotransferase (AST), Any Grade Increase110
AST, Increase to Grade 3000
AST, Increase to Grade 4000
Bilirubin, Any Grade Increase010
Bilirubin, Increase to Grade 3000
Bilirubin, Increase to Grade 4000
Creatinine, Any Grade Increase233
Creatinine, Increase to Grade 3000
Creatinine, Increase to Grade 4000
Potassium, Any Grade Increase021
Potassium, Increase to Grade 3000
Potassium, Increase to Grade 4000
Lactate Dehydrogenase, Any Grade Increase123
Lactate Dehydrogenase, Increase to Grade 3000
Lactate Dehydrogenase, Increase to Grade 4000
Sodium, Any Grade Increase000
Sodium, Increase to Grade 3000
Sodium, Increase to Grade 4000
Albumin, Any Grade Increase434
Albumin, Increase to Grade 3000
Albumin, Increase to Grade 4000
PrimaryPart 1: Number of Participants With Worst Case Clinical Chemistry Results by Maximum Grade Increase Post-Baseline Relative to Baseline (Arm 5)

Blood samples were collected for the analysis of clinical chemistry parameters and are categorized in alignment with Common Terminology Criteria for Adverse Events (CTCAE) version 5 as Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; and Grade 4: life-threatening consequences. Higher grade indicates greater severity. An increase in grade is defined relative to the Baseline grade. Participants with missing baseline values are assumed to have baseline value of grade 0. Any worst-case post baseline increase in grade along with any increase to a maximum grade of 3 and 4 is summarized. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

Time frame:
Up to approximately 107 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Worst Case Clinical Chemistry Results by Maximum Grade Increase Post-Baseline Relative to Baseline (Arm 5)
ParticipantsArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MDArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD
aPTT, Any Grade Increase0000
aPTT, Increase to Grade 30000
aPTT, Increase to Grade 40000
Glucose, Any Grade Increase0002
Glucose, Increase to Grade 30000
Glucose, Increase to Grade 40000
INR increased, Any Grade Increase0000
INR increased, Increase to Grade 30000
INR increased, Increase to Grade 40000
AP, Any Grade Increase3112
AP, Increase to Grade 30000
AP, Increase to Grade 40000
ALT, Any Grade Increase1013
ALT, Increase to Grade 30001
ALT, Increase to Grade 40000
AST, Any Grade Increase0232
AST, Increase to Grade 30000
AST, Increase to Grade 40000
Bilirubin, Any Grade Increase2020
Bilirubin, Increase to Grade 30000
Bilirubin, Increase to Grade 40010
Creatinine, Any Grade Increase3334
Creatinine, Increase to Grade 31001
Creatinine, Increase to Grade 40000
Potassium, Any Grade Increase1022
Potassium, Increase to Grade 30000
Potassium, Increase to Grade 40000
Lactate Dehydrogenase, Any Grade Increase2044
Lactate Dehydrogenase, Increase to Grade 30000
Lactate Dehydrogenase, Increase to Grade 40000
Sodium, Any Grade Increase0000
Sodium, Increase to Grade 30000
Sodium, Increase to Grade 40000
Albumin, Any Grade Increase6441
Albumin, Increase to Grade 30100
Albumin, Increase to Grade 40000
PrimaryPart 1: Number of Participants With Worst Case Change Post-baseline in Clinical Chemistry Parameters (Arm 4)

Blood samples were collected for analysis of clinical chemistry. The summaries of worst-case post baseline (WCPB) from baseline (B) with respect to normal range was analyzed. Data is presented as "XXX B YYY, WCPB YYY", where XXX denotes lab parameter and YYY is high/normal/low. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

Time frame:
Up to approximately 97 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Worst Case Change Post-baseline in Clinical Chemistry Parameters (Arm 4)
ParticipantsArm 4: Dostarlimab + Belrestotug [Low Dose (LD)]Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)]Arm 4: Dostarlimab + Belrestotug [High Dose (HD)]
Calcium, B High, WCPB High011
Calcium, B High, WCPB Normal000
Calcium, B High, WCPB Low000
Calcium, B Normal, WCPB High201
Calcium, B Normal, WCPB Normal405
Calcium, B Normal, WCPB Low001
Calcium, B Low, WCPB High020
Calcium, B Low, WCPB Normal070
Calcium, B Low, WCPB Low000
Lipase, B High, WCPB High000
Lipase, B High, WCPB Normal000
Lipase, B High, WCPB Low000
Lipase, B Normal, WCPB High112
Lipase, B Normal, WCPB Normal455
Lipase, B Normal, WCPB Low000
Lipase, B Low, WCPB High000
Lipase, B Low, WCPB Normal010
Lipase, B Low, WCPB Low000
Amylase, B High, WCPB High010
Amylase, B High, WCPB Normal000
Amylase, B High, WCPB Low000
Amylase, B Normal, WCPB High001
Amylase, B Normal, WCPB Normal446
Amylase, B Normal, WCPB Low110
Amylase, B Low, WCPB High000
Amylase, B Low, WCPB Normal000
Amylase, B Low, WCPB Low000
Urea, B High, WCPB High020
Urea, B High, WCPB Normal000
Urea, B High, WCPB Low000
Urea, B Normal, WCPB High110
Urea, B Normal, WCPB Normal115
Urea, B Normal, WCPB Low101
Urea, B Low, WCPB High000
Urea, B Low, WCPB Normal100
Urea, B Low, WCPB Low010
Free Triiodothyronine (T3), B High, WCPB High000
T3, B High, WCPB Normal000
T3, B High, WCPB Low000
T3, B Normal, WCPB High001
T3, B Normal, WCPB Normal124
T3, B Normal, WCPB Low121
T3, B Low, WCPB High000
T3, B Low, WCPB Normal000
T3, B Low, WCPB Low000
Free Thyroxine (T4), B High, WCPB High000
T4, B High, WCPB Normal000
T4, B High, WCPB Low000
T4, B Normal, WCPB High000
T4, B Normal, WCPB Normal465
T4, B Normal, WCPB Low010
T4, B Low, WCPB High001
T4, B Low, WCPB Normal000
T4, B Low, WCPB Low000
Troponin I, B High, WCPB High010
Troponin I, B High, WCPB Normal000
Troponin I, B High, WCPB Low000
Troponin I, B Normal, WCPB High020
Troponin I, B Normal, WCPB Normal103
Troponin I, B Normal, WCPB Low000
Troponin I, B Low, WCPB High000
Troponin I, B Low, WCPB Normal000
Troponin I, B Low, WCPB Low000
Thyrotropin, B High, WCPB High100
Thyrotropin, B High, WCPB Normal000
Thyrotropin, B High, WCPB Low000
Thyrotropin, B Normal, WCPB High010
Thyrotropin, B Normal, WCPB Normal342
Thyrotropin, B Normal, WCPB Low015
Thyrotropin, B Low, WCPB High000
Thyrotropin, B Low, WCPB Normal100
Thyrotropin, B Low, WCPB Low000
PrimaryPart 1: Number of Participants With Worst Case Change Post-baseline in Clinical Chemistry Parameters (Arm 5)

Blood samples were collected for analysis of clinical chemistry. The summaries of worst-case post baseline (WCPB) from baseline (B) with respect to normal range was analyzed. Data is presented as "XXX B YYY, WCPB YYY", where XXX denotes lab parameter and YYY is high/normal/low. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Worst Case Post-Baseline includes all scheduled and unscheduled visits post baseline.

Time frame:
Up to approximately 107 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Worst Case Change Post-baseline in Clinical Chemistry Parameters (Arm 5)
ParticipantsArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MDArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD
Calcium, B High, WCPB High0000
Calcium, B High, WCPB Normal0001
Calcium, B High, WCPB Low0000
Calcium, B Normal, WCPB High0100
Calcium, B Normal, WCPB Normal9578
Calcium, B Normal, WCPB Low1131
Calcium, B Low, WCPB High0000
Calcium, B Low, WCPB Normal0010
Calcium, B Low, WCPB Low0000
Lipase, B High, WCPB High2000
Lipase, B High, WCPB Normal0000
Lipase, B High, WCPB Low0000
Lipase, B Normal, WCPB High0123
Lipase, B Normal, WCPB Normal5266
Lipase, B Normal, WCPB Low0010
Lipase, B Low, WCPB High0000
Lipase, B Low, WCPB Normal0000
Lipase, B Low, WCPB Low0010
Amylase, B High, WCPB High1111
Amylase, B High, WCPB Normal0000
Amylase, B High, WCPB Low0000
Amylase, B Normal, WCPB High0022
Amylase, B Normal, WCPB Normal6176
Amylase, B Normal, WCPB Low0000
Amylase, B Low, WCPB High0000
Amylase, B Low, WCPB Normal0100
Amylase, B Low, WCPB Low0000
Urea, B High, WCPB High2100
Urea, B High, WCPB Normal0000
Urea, B High, WCPB Low0000
Urea, B Normal, WCPB High1124
Urea, B Normal, WCPB Normal2433
Urea, B Normal, WCPB Low1011
Urea, B Low, WCPB High0000
Urea, B Low, WCPB Normal0000
Urea, B Low, WCPB Low0000
Free Triiodothyronine (T3), B High, WCPB High0010
T3, B High, WCPB Normal0000
T3, B High, WCPB Low0000
T3, B Normal, WCPB High1010
T3, B Normal, WCPB Normal3368
T3, B Normal, WCPB Low1011
T3, B Low, WCPB High0000
T3, B Low, WCPB Normal0000
T3, B Low, WCPB Low2100
Free Thyroxine (T4), B High, WCPB High0101
T4, B High, WCPB Normal0000
T4, B High, WCPB Low0000
T4, B Normal, WCPB High0010
T4, B Normal, WCPB Normal7378
T4, B Normal, WCPB Low1010
T4, B Low, WCPB High0000
T4, B Low, WCPB Normal0000
T4, B Low, WCPB Low0000
Troponin I, B High, WCPB High0000
Troponin I, B High, WCPB Normal0000
Troponin I, B High, WCPB Low0000
Troponin I, B Normal, WCPB High0010
Troponin I, B Normal, WCPB Normal2156
Troponin I, B Normal, WCPB Low0000
Troponin I, B Low, WCPB High0000
Troponin I, B Low, WCPB Normal0000
Troponin I, B Low, WCPB Low0000
Thyrotropin, B High, WCPB High2110
Thyrotropin, B High, WCPB Normal0001
Thyrotropin, B High, WCPB Low0000
Thyrotropin, B Normal, WCPB High2110
Thyrotropin, B Normal, WCPB Normal5357
Thyrotropin, B Normal, WCPB Low0021
Thyrotropin, B Low, WCPB High0000
Thyrotropin, B Low, WCPB Normal0010
Thyrotropin, B Low, WCPB Low0000
PrimaryPart 1: Number of Participants With Worst-Case Urinalysis Results Post-Baseline Relative to Baseline (Arm 4)

Urinalysis was performed. Participants with missing value at baseline are assumed to be negative at baseline. All increases are from baseline. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Up to approximately 97 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Worst-Case Urinalysis Results Post-Baseline Relative to Baseline (Arm 4)
ParticipantsArm 4: Dostarlimab + Belrestotug [Low Dose (LD)]Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)]Arm 4: Dostarlimab + Belrestotug [High Dose (HD)]
Occult Blood, No Change/Decreased467
Occult Blood, Any Increase111
Occult Blood, Unknown000
Protein, No Change/Decreased327
Protein, Any Increase241
Protein, Unknown010
PrimaryPart 1: Number of Participants With Worst-Case Urinalysis Results Post-Baseline Relative to Baseline (Arm 5)

Urinalysis was performed. Participants with missing value at baseline are assumed to be negative at baseline. All increases are from baseline. Baseline is defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Up to approximately 107 weeks
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Worst-Case Urinalysis Results Post-Baseline Relative to Baseline (Arm 5)
ParticipantsArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MDArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD
Occult Blood, No Change/Decreased4566
Occult Blood, Any Increase4052
Occult Blood, Unknown2100
Protein, No Change/Decreased3557
Protein, Any Increase5161
Protein, Unknown0000
PrimaryPart 2: Overall Survival (OS)

OS is defined as the time from date of randomization to the date of death, irrespective of the cause of death.

Time frame:
Up to approximately 107 weeks

No measurements were reported for this outcome.

SecondaryPart 1: Objective Response Rate (ORR) (Arm 4)

ORR is defined as the percentage of participants with a best overall confirmed Complete response (CR) or Partial response (PR) at any time as per disease-specific criteria per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Complete Response (CR) is defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline).

Time frame:
Up to approximately 97 weeks
Reported as:
Number · Percentage of Participants
Part 1: Objective Response Rate (ORR) (Arm 4)
Percentage of ParticipantsArm 4: Dostarlimab + Belrestotug [Low Dose (LD)]Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)]Arm 4: Dostarlimab + Belrestotug [High Dose (HD)]
Part 1: Objective Response Rate (ORR) (Arm 4)0 (0.0 to 45.9)0 (0.0 to 33.6)0 (0.0 to 33.6)
SecondaryPart 1: Objective Response Rate (ORR) (Arm 5)

ORR is defined as the percentage of participants with a best overall confirmed CR or PR at any time as per disease-specific criteria per RECIST version 1.1. CR is defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline).

Time frame:
Up to approximately 107 weeks
Reported as:
Number · Percentage of Participants
Part 1: Objective Response Rate (ORR) (Arm 5)
Percentage of ParticipantsArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MDArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD
Part 1: Objective Response Rate (ORR) (Arm 5)0 (0.0 to 30.8)0 (0.0 to 41.0)9 (0.2 to 41.3)0 (0.0 to 30.8)
SecondaryPart 1: Disease Control Rate (DCR) (Arm 4)

DCR is defined as the percentage of participants with a confirmed CR + PR at any time, plus SD =\>12 weeks as per RECIST v1.1. Complete Response (CR) is defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.

Time frame:
Up to approximately 97 weeks
Reported as:
Number · Percentage of Participants
Part 1: Disease Control Rate (DCR) (Arm 4)
Percentage of ParticipantsArm 4: Dostarlimab + Belrestotug [Low Dose (LD)]Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)]Arm 4: Dostarlimab + Belrestotug [High Dose (HD)]
Part 1: Disease Control Rate (DCR) (Arm 4)17 (0.4 to 64.1)22 (2.8 to 60.0)11 (0.3 to 48.2)
SecondaryPart 1: Disease Control Rate (DCR) (Arm 5)

DCR is defined as the percentage of participants with a confirmed CR + PR at any time, plus SD =\>12 weeks as per RECIST v1.1. Complete Response (CR) is defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.

Time frame:
Up to approximately 107 weeks
Reported as:
Number · Percentage of Participants
Part 1: Disease Control Rate (DCR) (Arm 5)
Percentage of ParticipantsArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MDArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD
Part 1: Disease Control Rate (DCR) (Arm 5)40 (12.2 to 73.8)14 (0.4 to 57.9)27 (6.0 to 61.0)0 (0.0 to 30.8)
SecondaryPart 1: Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of Belrestotug (Arm 4)

Blood samples were collected for pharmacokinetic analysis of Belrestotug.

Time frame:
Up to 21 days (Cycle 1)
Reported as:
Mean · Microgram/ millilitre (ug/mL)
Part 1: Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of Belrestotug (Arm 4)
Microgram/ millilitre (ug/mL)Arm 4: Dostarlimab + Belrestotug [Low Dose (LD)]Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)]Arm 4: Dostarlimab + Belrestotug [High Dose (HD)]
Cmax88.470 ± 92.2653118.762 ± 46.4217271.835 ± 77.5244
Cmin9.412 ± 5.626422.091 ± 8.422444.350 ± 24.4184
SecondaryPart 1: Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of Belrestotug (Arm 5)

Blood samples were collected for pharmacokinetic analysis of Belrestotug.

Time frame:
Up to 21 days (Cycle 1)
Reported as:
Mean · ug/mL
Part 1: Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of Belrestotug (Arm 5)
ug/mLArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MDArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD
Cmax126.386 ± 21.8676137.837 ± 34.5390153.377 ± 33.515422.967 ± 7.0701
Cmin19.408 ± 6.410320.752 ± 11.5836153.069 ± 54.345021.693 ± 9.2699
SecondaryPart 1: Cmax and Cmin of Dostarlimab (Arm 4)

Blood samples were collected for pharmacokinetic analysis of Dostarlimab.

Time frame:
Up to 21 days (Cycle 1)
Reported as:
Mean · ug/mL
Part 1: Cmax and Cmin of Dostarlimab (Arm 4)
ug/mLArm 4: Dostarlimab + Belrestotug [Low Dose (LD)]Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)]Arm 4: Dostarlimab + Belrestotug [High Dose (HD)]
Cmax119.400 ± 60.9173124.278 ± 40.602697.433 ± 34.2035
Cmin33.900 ± 15.345434.071 ± 8.563822.935 ± 7.9792
SecondaryPart 1: Cmax and Cmin of Dostarlimab (Arm 5)

Blood samples were collected for pharmacokinetic analysis of Dostarlimab.

Time frame:
Up to 21 days (Cycle 1)
Reported as:
Mean · ug/mL
Part 1: Cmax and Cmin of Dostarlimab (Arm 5)
ug/mLArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MDArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD
Cmax108.920 ± 32.2323126.857 ± 51.083068.751 ± 43.8090109.330 ± 121.1920
Cmin29.290 ± 12.451934.550 ± 13.296034.218 ± 12.390039.013 ± 26.8319
SecondaryPart 1: Cmax and Cmin of Nelistotug (Arm 5)

Blood samples were collected for pharmacokinetic analysis of Nelistotug.

Time frame:
Up to 21 days (Cycle 1)
Reported as:
Mean · ug/mL
Part 1: Cmax and Cmin of Nelistotug (Arm 5)
ug/mLArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MDArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HD
Cmax299.889 ± 313.2561479.714 ± 219.714875.580 ± 12.4318554.750 ± 140.7792
Cmin43.689 ± 13.724088.243 ± 34.720115.070 ± 2.9601123.975 ± 66.4588
SecondaryPart 2: Survival Rate at 12 and 18 Months

Survival rate was planned to be anaysed at 12 and 18 months

Time frame:
At 12 and 18 months

No measurements were reported for this outcome.

SecondaryPart 2: Number of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD) and Progressive Disease (PD)

CR, PR, SD and PD was planned to be evaluated as per RECIST version 1.1 criteria. Complete Response (CR) is defined as disappearance of all target and non-target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease. Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm.

Time frame:
Up to approximately 107 weeks

No measurements were reported for this outcome.

SecondaryPart 2: Progression-free Survival (PFS)

PFS is defined as time from the date of randomization to the date of disease progression as per RECIST v1.1. or death whichever occurs earlier. Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm.

Time frame:
Up to approximately 107 weeks

No measurements were reported for this outcome.

SecondaryPart 2: Objective Response Rate (ORR)

ORR is defined as the percentage of participants with a best overall confirmed Complete response (CR) or Partial response (PR) at any time as per disease-specific criteria per RECIST version 1.1. Complete Response (CR) is defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline).

Time frame:
Up to approximately 107 weeks

No measurements were reported for this outcome.

SecondaryPart 2: Duration of Response (DOR)

DOR is defined as the time for first documented evidence of CR or PR until disease progression or death, per RECIST 1.1 criteria. Complete Response (CR) is defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

Time frame:
Up to approximately 107 weeks

No measurements were reported for this outcome.

SecondaryPart 2: Disease Control Rate (DCR)

DCR is defined as the percentage of participants with a confirmed CR + PR at any time, plus SD =\>12 weeks as per RECIST v1.1. Complete Response (CR) is defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.

Time frame:
Up to approximately 107 weeks

No measurements were reported for this outcome.

SecondaryPart 2: Number of Participants With Immune-based (i) Complete Response (iCR), Partial Response (iPR), Unconfirmed Progressive Disease (iUPD), Confirmed Progressive Disease (iCPD), and Stable Disease (iSD)

Modified RECIST 1.1 for immune-based therapeutics (iRECIST) is based on RECIST v 1.1 but adapted to account for the unique tumor response seen with immunotherapeutic drugs. iRECIST is used to assess tumor response and progression and make treatment decisions. iCR: disappearance of all target lesions; iPR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters (e.g. percent change from baseline). iCPD: either 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; iSD: stable disease in the absence of CR or PD and iUPD: unconfirmed progressive disease when PD is unconfirmed and NE: not evaluable.

Time frame:
Up to approximately 107 weeks

No measurements were reported for this outcome.

SecondaryPart 2: Progression-free Survival (iPFS)

iPFS is defined as time from the date of randomization to the date of disease progression or death, whichever occurs earlier, per iRECIST criteria. Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm.

Time frame:
Up to approximately 107 weeks

No measurements were reported for this outcome.

SecondaryPart 2: Objective Response Rate (iORR)

iORR is defined as the percentage of participants with a confirmed iCR or iPR at any time per iRECIST criteria. iCR is defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. iPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

Time frame:
Up to approximately 107 weeks

No measurements were reported for this outcome.

SecondaryPart 2: Duration of Response (iDOR)

iDOR is defined as the time from first documented evidence of CR or PR until disease progression or death, per iRECIST criteria. iCR is defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. iPR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters.

Time frame:
Up to approximately 107 weeks

No measurements were reported for this outcome.

SecondaryPart 2: Number of Participants With AEs, SAEs, Adverse Events of Special Interest (AESI), AE/SAEs Leading to Dose Modifications/Delays/Withdrawals

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, any other situation such as important medical events according to medical or scientific judgement. AESI are considered to be Infusion Related Reactions (IRRs) and those of potential immunologic etiology. AEs were planned to be coded using the MedDRA coding system.

Time frame:
Up to approximately 107 weeks

No measurements were reported for this outcome.

SecondaryPart 2: Number of Participants With Clinically Significant Changes in Vital Signs and Laboratory Parameters

Clinically significant changes in vital signs were planned to be assessed. Blood samples were planned to be collected for the analysis of laboratory parameters.

Time frame:
Up to approximately 107 weeks

No measurements were reported for this outcome.

SecondaryPart 2: Cmax and Cmin for Dostarlimab

Blood samples were planned to be collected to assess the pharmacokinetics of Dostarlimab.

Time frame:
Up to approximately 107 weeks

No measurements were reported for this outcome.

SecondaryPart 2: Cmax and Cmin for Belrestotug

Blood samples were planned to be collected to assess the pharmacokinetics of Belrestotug.

Time frame:
Up to approximately 107 weeks

No measurements were reported for this outcome.

SecondaryPart 2: Number of Participants With Positive Anti-drug Antibodies (ADA)

Serum samples were planned to be collected for the analysis of the presence of ADAs using validated immunoassays.

Time frame:
Up to approximately 107 weeks

No measurements were reported for this outcome.

Adverse events

Collected over All cause mortality, non-SAEs and SAEs were collected up to approximately 97 weeks for arm 4 and up to approximately 107 weeks for arm 5.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 4: Dostarlimab + Belrestotug [Low Dose (LD)]4/6 (66.7%)0/6 (0%)6/6 (100%)
Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)]5/9 (55.6%)3/9 (33.3%)9/9 (100%)
Arm 4: Dostarlimab + Belrestotug [High Dose (HD)])7/9 (77.8%)2/9 (22.2%)8/9 (88.9%)
Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MD7/10 (70%)3/10 (30%)10/10 (100%)
Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HD4/7 (57.1%)3/7 (42.9%)6/7 (85.7%)
Arm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LD7/11 (63.6%)3/11 (27.3%)11/11 (100%)
Arm 5 Randomized Part: Belrestotug(MD) + Dostarlimab + Nelistotug (HD)6/10 (60%)3/10 (30%)9/10 (90%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventArm 4: Dostarlimab + Belrestotug [Low Dose (LD)]Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)]Arm 4: Dostarlimab + Belrestotug [High Dose (HD)])Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MDArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LDArm 5 Randomized Part: Belrestotug(MD) + Dostarlimab + Nelistotug (HD)
Febrile neutropeniaBlood and lymphatic system disorders0/60/90/90/101/70/110/10
DysphagiaGastrointestinal disorders0/60/90/90/101/70/110/10
COVID-19 pneumoniaInfections and infestations0/60/90/90/101/70/110/10
PneumoniaInfections and infestations0/61/90/90/101/70/110/10
EpilepsyNervous system disorders0/60/90/90/101/70/110/10
Immune-mediated myocarditisCardiac disorders0/61/90/90/100/70/110/10
Pneumonia staphylococcalInfections and infestations0/60/91/90/100/70/110/10
SepsisInfections and infestations0/61/90/90/100/71/110/10
Ischaemic strokeNervous system disorders0/61/90/90/100/70/110/10
NephrolithiasisRenal and urinary disorders0/60/91/90/100/70/110/10
Most frequent other events
Showing 10 of 164
Most frequent other events
EventArm 4: Dostarlimab + Belrestotug [Low Dose (LD)]Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)]Arm 4: Dostarlimab + Belrestotug [High Dose (HD)])Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MDArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LDArm 5 Randomized Part: Belrestotug(MD) + Dostarlimab + Nelistotug (HD)
Infusion related reactionInjury, poisoning and procedural complications1/61/93/90/103/75/111/10
Decreased appetiteMetabolism and nutrition disorders2/64/91/91/101/72/112/10
VomitingGastrointestinal disorders2/60/90/91/100/71/110/10
Oedema peripheralGeneral disorders0/63/91/91/100/72/111/10
PruritusSkin and subcutaneous tissue disorders2/63/92/92/101/72/113/10
RashSkin and subcutaneous tissue disorders2/61/91/92/102/71/111/10
Chest painGeneral disorders0/61/90/92/100/71/113/10
AnaemiaBlood and lymphatic system disorders0/61/90/91/102/70/111/10
PyrexiaGeneral disorders1/62/91/90/102/70/110/10
Weight decreasedInvestigations1/61/91/90/102/72/111/10

Baseline characteristics

Age, Customized
Age, Customized(Participants)Arm 4: Dostarlimab + Belrestotug [Low Dose (LD)]Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)]Arm 4: Dostarlimab + Belrestotug [High Dose (HD)]Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MDArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HDTotal
18 to >=85 years699107111062
Sex: Female, Male
Sex: Female, Male(Participants)Arm 4: Dostarlimab + Belrestotug [Low Dose (LD)]Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)]Arm 4: Dostarlimab + Belrestotug [High Dose (HD)]Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MDArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HDTotal
Female334534426
Male365547636
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 4: Dostarlimab + Belrestotug [Low Dose (LD)]Arm 4: Dostarlimab + Belrestotug [Medium Dose (MD)]Arm 4: Dostarlimab + Belrestotug [High Dose (HD)]Arm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug MDArm 5 Safety Part: Belrestotug MD + Dostarlimab + Nelistotug HDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug LDArm 5 Randomized Part: Belrestotug MD + Dostarlimab + Nelistotug HDTotal
American Indian or Alaska Native00000000
Asian00001023
Native Hawaiian or Other Pacific Islander10000001
Black or African American00000000
White4781068548
More than one race00000000
Unknown or Not Reported121003310
08

Study locations

15 sites
  • GSK Investigational SIte
    Nashville, Tennessee 37203, United States
  • GSK Investigational Site
    Edmonton, Alberta T6G 1Z2, Canada
  • GSK Investigational Site
    Brampton, Ontario L6R 3J7, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2M9, Canada
  • GSK Investigational Site
    Bordeaux, 33076, France
  • GSK Investigational Site
    Paris, 75018, France
  • GSK Investigational Site
    Paris, 75248, France
  • GSK Investigational Site
    Villejuif, 94805, France
  • GSK Investigational Site
    Großhansdorf, 22927, Germany
  • GSK Investigational Site
    Meldola FC, 47014, Italy
  • GSK Investigational Site
    Milan, 20133, Italy
  • GSK Investigational Site
    Siena, 53100, Italy
  • GSK Investigational Site
    Barcelona, 08035, Spain
  • GSK Investigational Site
    Madrid, 28034, Spain
  • GSK Investigational Site
    Málaga, 29010, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in May 2024, 28 months.

Results were first posted in Jul 2025, 1 year 2 months after primary completion.

Of 179 industry-sponsored phase 2 interventional studies under Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's 28 months is below that.

Counting every sponsor, half of 514 studies reached it within 52 months; a quarter within 33 and three quarters within 92.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2025
First posted
Apr 14, 2025
StartActual
Dec 23, 2021
Primary completionActual
May 2, 2024
CompletionActual
May 2, 2024
Results first posted
Jul 3, 2025
Last update
Jul 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06926673
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 14, 2025
Start date
Dec 23, 2021
Primary completion
May 2, 2024
Completion
May 2, 2024
Results posted
Jul 3, 2025
Last update
Jul 3, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nelistotug

Start the discussion